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THE BETA-BLOCKER PARADOX
CIBIS III completes a fundamental scientific phase
of a sequence of large clinical trials (1-7) which has
established the current therapeutic principles for the
management of chronic heart failure (CHF) patients
(8). These comprise the use of ACE inhibitors and be-
ta-blockers. However, while ACE inhibitors, by an-
tagonizing the synthesis of angiotensin II, found their
natural pathway from hypertension into CHF, beta-
blockers followed a controversial trail. They ap-
peared effective in the BEHAT (9) trial after myocar-
dial infarction (MI) even in patients with depressed
left ventricular (LV) function. Nonetheless, the gener-
al view of CHF as an almost exclusively cardio-circu-
latory mechanical disease/remodelling led to the use
of inotropic interventions, with non-infrequent nega-
tive consequences on mortality (10). Furthermore,
this view prevented the conception of using anti-
adrenergic interventions in CHF which consequently
remained a strong contraindication to the use of be-
ta-blockers for many years.  Beginning with CIBIS II,
a number of trials have proven that beta-blocker
therapy improves survival in CHF, with a specific ac-
tion on arrhythmic sudden cardiac death (SCD) in pa-
tients with optimum background therapy, including
the use of ACE inhibitors. This did not happen by
chance, as a strong experimental ground had already
existed and has further grown during the last few
years (11); very soon after its first manifestation, is-
chemic heart disease triggers a profound remodel-
ling of the autonomic nervous system, resulting in re-
ceptor changes and sprouting of neural fibers (12,
13). In line with this background stands the huge
amount of clinical evidence documenting the anti-
fibrillatory action of anti-adrenergic interventions. In
contrast to the rapid activation of the autonomic ner-
vous system, the renin-angiotensin system (RAS)
acts primarily by promoting the progressive myocar-
dial architectural changes, leading to inefficient LV
function and pump failure (14). The same process in-
directly contributes to the genesis of an arrhythmo-
genic substrate for SCD to occur (15, 16). However,
despite the bulk of evidence documenting the strik-
ing efficacy of ACE inhibitors and, more so, of beta-
blockers in CHF, both drugs are underused. Recent
surveys indicate that ACE inhibitors are given to only
60% of eligible patients (17) (Fig. 1) and the picture
for beta-blockers is even worse, as the percentage of
treated patients among those eligible is as low as
around 30%. Additionally, beta-blocker therapy is
mostly given to low risk patients and as late as 6
months after a first hospitalisation for HF (18). The
immediate consequence of the mistrust in (or fear of)
using adequate pharmacological therapy according
to the international guidelines has been the boosted
use of implantable cardioverter defibrillators (ICD) in
any patient with  depressed LV systolic function.
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In this complex scenario, CIBIS III (19) has recent-
ly documented that beta-blocker therapy with biso-
prolol can be effectively and safely initiated even pri-
or to ACE inhibition, thus refuting the general view
that this latter was a “conditio sine qua non” before
considering anti-adrenergic interventions. Some in-
triguing information that emerged from CIBIS III was
also a 31% all-cause mortality reduction at one year,
which however did not quite reach statistical signifi-
cance, possibly because of the limited sample size
(Fig. 2).  
Usually the drug initiated first attains a higher dose
and, indeed, CIBIS III has shown that the initial use of
bisoprolol, prior to starting ACE inhibition, allows up-
titration to a higher dose of adrenergic inhibition. This
offers a greater number of patients the benefit from
beta-blockade, not only during initiation of therapy
but also during combined therapy with subsequent
ACE inhibition. Although the analyses in CIBIS III
showed that all subgroups benefited nearly equally
from a beta-blocker-first strategy, it may seem rea-
sonable to propose that bisoprolol should be started
first in patients with previous myocardial infarction,
early stages of CHF or with tachycardia or ventricular
tachiarrhythmias, i.e. at high risk for SCD. Thus, if
SCD prevention is what matters most in the early
stage of CHF, one should consider some changes in
the recommendations of the current guidelines.
Combining the initial evidence from CIBIS III with the
44% SCD risk reduction observed in CIBIS II, sup-
ports the hypothesis that early introduction of biso-
prolol in CHF patients, and the consequent optimal
up-titration of the drug, could provide a more effec-
tive SCD prevention strategy compared to what has
been seen so far. Patients can subsequently benefit
from the combination therapy with beta-blockade
and ACE inhibition. 
THE CIBIS III: OPTIMAL PHARMACOLOGICAL
STRATEGY FOR SD PREVENTION
CIBIS III randomised 1010 patients with mild or
moderate, stable CHF and left ventricular ejection
fraction ≤35%, without ACE inhibitor, betablocker or
angiotensin-receptor-blocker therapy, to open-label
monotherapy with either bisoprolol (target dose 10
mg o.d., n = 505) or enalapril (target dose 10 mg
Fig. 1 - The improvement International Survey: 1363 Physicians’
practises, 15 countries, 11062 CHF patients. Percentage of eligi-
ble patients with heart failure receiving pharmacological treat-
ment.
Fig. 2 - Kaplan-Meier plot of survival at one year in the intention-
to-treat sample.Vanoli et al
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b.i.d., n = 505) for six months, followed by their com-
bination for 6-24 months. The two strategies were re-
cently blindly compared regarding sudden death.  
The masked adjudication was done by the end-
point committee and 3 members of the steering com-
mittee and sudden death was defined according to
the following criteria: 
1) Death occurring within one hour of the occurrence
of new symptoms or without symptoms.
2) Death at night during sleep (patient found dead in
bed) without other cause.
3) Death in odd places (e.g. toilet room, parking lot,
etc) without other cause.
4) Death within 28 days after resuscitation from car-
diac arrest in the absence of pre-existing circula-
tory failure or other causes of death. 
5) Unwitnessed death in the absence of pre-existent
progressive circulatory failure or other causes of
death.
The most striking finding from this new analysis
(20) was that, during the 6-month monotherapy
phase, 8 of 23 deaths in the bisoprolol-first group
were sudden, compared to 16 of 32 in the enalapril-
first group: hazard ratio (HR) for sudden death 0.50;
95% confidence interval (CI) 0.21-1.16; P=0.107. At
one year, 16 of 42 versus 29 of 60 deaths were sud-
den: HR 0.54; 95% CI 0.29-1.00; P=0.049.  At study
end, 29 of 65 versus 34 of 73 deaths were sudden:
HR 0.84; 95% CI 0.51-1.38; P=0.487 (Fig. 3). There
were no significant between-group differences in any
other fatal events. In the bisoprolol-first group, there
was an early non-significant increase in patients hos-
pitalized for worsening of CHF, diminishing during
combined therapy. This might be explained by the
phenomenon of competing risks, since more patients
survived in the bisoprolol-first group.
Thus, CIBIS III is now documenting that in patients
with mildly or moderately symptomatic, stable CHF
and 35% or less left ventricular ejection fraction
starting treatment for CHF with the betablocker biso-
prolol, may importantly decrease early sudden
deaths, as compared to the ACE inhibitor enalapril.
The benefit generated within the first 6 months ex-
tended to a significant SD reduction by one year. Fur-
ther analyses are needed, though, to comprehend
what happened later in the follow up that partly an-
nuled the benefit observed in the first 12 months. 
The number of patients dying from a sudden death
in the enalapril-first group during the first six months
of monotherapy was equal to that in the bisoprolol-
first group during the entire first year. The difference
in sudden deaths was accompanied by a similar re-
duction in all-cause mortality, although not statisti-
cally significant. Consequently, bisoprolol-first did
not shift the mode of death from sudden death to
death due to progressive CHF or other type of non-
sudden death, either on the short or longer term.  
Prior to the CIBIS III trial, a betablocker and an
ACE inhibitor in monotherapy or as first CHF treat-
ment were never directly compared with regard to the
effects on sudden death (or all-cause death or hospi-
Fig. 3 - Sudden death during the first year. At one year, in the biso-
prolol-first group 16 patients had a sudden death versus 29 in the
enalapril-first group: HR for sudden death, bisoprolol-first versus
enalapril-first 0.54; 95% CI 0.29-1.00: P=0.049.
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talisation) in patients with CHF.  However, assess-
ment of the effects of ACE inhibitors versus placebo
(on top of a diuretic with or without digitalis) and of
betablockers versus placebo (on top of an ACE in-
hibitor and diuretics with or without digitalis) indi-
cates that betablockers substantially reduce sudden
death, whereas there is no such evidence for ACE in-
hibitors.  The results of the monotherapy phase in
CIBIS III constitute the first data on a direct compar-
ison between a betablocker, bisoprolol, and an ACE
inhibitor, enalapril, in regard to the effect on sudden
death.  The results of the entire CIBIS III represent the
first large-scale data comparing a strategy of begin-
ning treatment for CHF with a betablocker followed
by an ACE inhibitor with the standard regimen of an
ACE inhibitor first, followed by a betablocker.  The
findings of CIBIS III are in agreement with those of
prior trials regarding the superior effects of
betablockers on sudden death and have the potential
to affect clinical practice. The minor increase in risk
of early worsening CHF, if any, might be a reasonable
price to pay for an early reduction in sudden deaths,
also in view of the fact that appropriate diuretic regi-
men as recommended by the international guidelines
would likely prevent this from happening. 
On the other hand, one may argue that the order of
initiating a betablocker and an ACE inhibitor in pa-
tients with CHF does not matter, since both should
be given to patients with CHF and impaired left ven-
tricular systolic function.  However, surveys show
that the second agent is most often not started soon
after the first drug and is frequently not given at all,
and when it is prescribed it is usually given in a low
dose.  Even under the clinical trial conditions of
CIBIS III, where investigators were forced to up-
titrate both study drugs according to protocol unless
they had a very good reason for not doing so, the
mean dose of bisoprolol at one year was significant-
ly higher in the bisoprolol-first group compared to the
enalapril-first group. Furthermore, even if one were
to give patients both treatments, the observation of
an early sudden death reduction in the bisoprolol-
first group indicates the need to give CHF patients a
betablocker as soon as possible.  
These data do not argue against the growing use
of ICD but, once more, point to the fact that manage-
ment of SD risk still leaves plenty of room for imple-
mentation that can be attained by understanding and
applying the appropriate concepts for adequate
pharmacological regimens. Optimal beta-blocker
therapy instated very early after the disease identifi-
cation may prevent a number of still active individu-
als from dying suddenly. Once adequately instated,
combined beta-blockade and ACE-inhibition do con-
stitute a solid ground for the effective use of devices.
It should indeed not be overlooked that, in MADIT II,
full beta-blocker therapy significantly decreased
mortality and ICD appropriate discharges (21). 
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